Unique GPCR antibody discovery platform, fibrosis and autoimmune disease projects obtained through this platform (LPA1, CXCR3, CCR7 and EP4 projects)

NBHL is a biotechnology company focused on the discovery and development of innovative therapeutic GPCR-targeting antibodies for fibrosis, autoimmune, inflammation and cancer.

Would you be available during the conference to discuss the alliance opportunity?

1.     GPCR antibody discovery platform collaboration

Our GPCR antibody discovery platform, MOGRAA, enables the rapid generation of highly diverse antibodies. Through our platform, we offer you the opportunity to efficiently and rapidly find the antibody for your desired GPCR target.

2.     　　Anti LPA1 Antibody for fibrosis (IPF, NASH and renal fibrosis)

The NBHL antibody is the first in its class to be fully antagonistic to LPA1. It is highly selective for both human and mouse LPA1 and has shown more potent antagonistic activity than existing small molecule compounds in Phase III studies. Positive results were obtained in the mouse bleomycin IPF model and the humanized antibody was successfully developed.

3.     　Anti CXCR3 Antibody for autoimmune such as Polymyositis and dermatomyositis

The NBHL antibody has high binding and inhibitory activity in T-cell chemotaxis assays. We have also been successful in developing humanized antibodies with high activity. POC studies in animal models are planned for the future.

4.     　Anti EP4 for autoimmune such as ankylosing spondylitis

NBHL antibody is a first-in-class antagonist antibody to EP4. Anti-EP4 is superior to small molecules in PK and selectivity. The antibody inhibits human Th17 function through EP4. The antibody can be used for dermatitis. 

5.     　Anti CCR7 for T/B lymphoma and gastrointestinal cancer

The antibody has strong ADCC activity against cancer cells expressing CCR7. NBHL's antibody directly inhibits CCR7 function activated by CCR7 ligands. The in vivo data suggest that anti-CCR7 treatment prevents lymphoma and solid tumor infiltration into lymphoid tissues.